Sharp Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-3.26	-3.56	-3.88
Depreciation & Amortization	0.1	0.11	0.13
Stock-Based Compensation	0.01	0.03	0.08
Other Operating Activities	-0.53	1.3	1.47
Change in Accounts Payable	0.05	0.18	0.16
Change in Other Net Operating Assets	0.01	-0.02	0
Operating Cash Flow	-3.62	-1.96	-2.05
Capital Expenditures	-0.01	-0.01	-
Other Investing Activities	0.01	-	-
Investing Cash Flow	-0.01	-0.01	-
Long-Term Debt Issued	2.2	-	-
Short-Term Debt Repaid	-0.24	-	-
Long-Term Debt Repaid	-0.2	-0.2	-0.18
Total Debt Repaid	-0.44	-0.2	-0.18
Net Debt Issued (Repaid)	1.76	-0.2	-0.18
Issuance of Common Stock	4.96	2.38	1.2
Financing Cash Flow	6.73	2.18	1.02
Foreign Exchange Rate Adjustments	0.01	-	-
Net Cash Flow	3.11	0.21	-1.03
Free Cash Flow	-3.63	-1.97	-2.05
Free Cash Flow Per Share	-0.40	-0.45	-14.77
Levered Free Cash Flow	-1.34	-1.23	-
Unlevered Free Cash Flow	-1.24	-1.12	-
Change in Net Working Capital	-0.26	-0.16	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.